Quick Win By The Algorithm: NKTR Release Third Quarter Results For Fiscal 2017

Quick Win By The Algorithm

Nektar Therapeutics is a clinical-stage biopharmaceutical company with a proven track record of discovering and developing new medicines that treat patients living with debilitating diseases and conditions. NKTR develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. Founded in 1990, Nektar Therapeutics has its headquarteres in San Francisco, California.

On November 7th, 2017, NKTR reported financial results for the third quarter ended September 30, 2017. The company showed huge improvements in comparison with the previous quarter and with the same quarter from the previous year.

NKTR’s total revenue for the 3 months ended September 30, 2017 grew to $152.9 million as compared to $36.3 million in the third quarter of 2016. Its year-to-date revenue for 2017 was $212.2 million, 65% higher then in the first nine months of 2016, when it was $128 million.

Moreover, the company’s operating costs and expenses increased as a results of increased research and development expense. NKTR’s R&D expenses for the first 9 months of the year grew from $153.6 million in 2016 to $187.0 million in 2017. R&D expenses were higher primarily because of expenses for pipeline programs, including Phase 3 clinical studies for NKTR-181, Phase 1/2 clinical studies of NKTR-214 and NKTR-358 and IND-enabling activities for NKTR-262 and NKTR-255.

Furthermore, NKTR net income in the third quarter of 2017 showed huge progress in comparison with the same quarter of 2016. It grew from a net loss of $43.2 million or $0.32 basic loss per share to a net income of $60.9 million or $0.39 basic income per share.

On November 12th, 2017, I Know First issued a bullish 1-month forecast for Nektar Therapeutics (NASDAQ: NKTR). The forecast showed a signal of 183.93 and a predictability of 0.13. In accordance with the forecast, NKTR’s stock returned 68.83% over this period, solidifying another quick win by the I Know First algorithm.

Current I Know First subscribers received this bullish NKTR forecast on November 12th, 2017


Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.